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Abstract
Statin-induced myopathy is a common adverse reaction of statin therapy. Patients with elevated
plasma concentration of statins are thought to be at greater risk for myopathy. Statins are
transported from the blood to hepatocytes via organic anion transporting polypeptide 1B1
(OATP1B1). Although single nucleotide polymorphisms (SNPs) in OATP1B1 have been
associated with increased statin concentrations, we hypothesize that there may be other SNPs
in OATP1B1 that can also contribute to reduced transport activity and increased plasma statin
concentrations. OATP1B1 cDNA packaged in pEF6/V5-His TOPO was used as template, and
6 SNPs — c.298G>A, c.419C>T, c.463C>A (*4), c.1007C>G, c.1463G>C (*9), and
c.1738C>T — were introduced separately and expressed in adenovirus. 3 SNPs abolished
transport activity, 1 SNP decreased transport, 1 increased transport, and 1 did not affect
transport activity. Our data support the hypothesis that there are additional loss of function
SNPs in OATP1B1.

Keywords
Pharmacogenomics, drug transporters, OATP, statins, statin-induced myopathy, single
nucleotide polymorphism, adverse drug reactions, personalized medicine
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Chapter 1

1

« Literature Review »

Human drug transporters are an important class of proteins that can affect
pharmacokinetics and clinical outcomes. Additionally, single nucleotide polymorphisms
(SNPs) in these transporters have emerged as a possible predictor of plasma drug levels,
and can be used to maximize drug efficacy and minimize toxicity. This chapter seeks to
introduce the classes of influx and efflux drug transporters, specifically the organic anion
transporting polypeptides (OATPs) family, and outline some important SNPs that have
been discovered in drug transporters. Finally, the chapter will discuss why this research
may have significant clinical contributions.

1.1 Nomenclature of human drug transporters
Membrane transporters are membrane-bound proteins that facilitate the movement of
compounds across a physiological barrier. Proper movement of compounds is essential for
electrochemical and hormonal homeostasis. Small, non-polar molecules are able to pass
through cell membranes by simple diffusion, but the movement of large polar molecules
as well the movement of molecules against their concentration gradient require the aid of
membrane transporters (1). Approximately 10% of all human genes are transporter-related,
coding for either the transporter themselves or accessory proteins like subunits or
regulatory proteins. Transporters are extremely diverse in their location and substrate
specificity. Most carry important endogenous molecules, and some can transport
exogenous compounds and drugs in addition to their endogenous ligands (2). These
transporters with exogenous substrates are called drug transporters and can play major roles
in a drug’s absorption, distribution, and elimination. Therefore, full understanding of these
transporters can greatly improve efficiency of drug discovery and development by being
able to predict and control the pharmacokinetic profile of the drug and its target site of
action (3).
Drug transporters are divided into two categories, the solute career (SLC) superfamily and
the ATP-binding cassette (ABC) superfamily. The ABC superfamily consists of efflux
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transporters that all have an ATP catalytic domain to generate energy to move compounds
against their concentration gradient. Families within the ABC superfamily are given
another letter (ABCB) based on sequence homology, and further division of individual
members are given a final number (ABCB1) based on order of discovery (4). The first
prominent drug transporter discovered was ABCB1 in 1976, also known as multi-drug
resistance protein 1 (MDR1), or P-glycoprotein (P-gp). It was located on the membrane of
mutant colchicine-resistant Chinese hamster ovary cells, and was found to have direct
correlation with degree of drug-resistance (5). The same protein was confirmed to exist in
humans and have since become the most extensively studied transporter. In 1992, another
transporter belonging to the ABC superfamily was discovered to convey drug resistance in
cells that did not express P-gp. This transporter was later named multidrug resistanceassociated protein 1 (MRP1), and given the gene name ABCC1 (6). Throughout the 1990s
and 2000s, advances in technology, methodology, and interest have catapulted the number
of transporters discovered. Today there is a total of 48 known members in the ABC
superfamily (4).
Contrary to the ABC superfamily, the SLC superfamily consists of uptake transporters that
do not use energy from ATP to mediate transport. These transporters include passive
transporters and ion exchangers/co-transporters. There are 52 members in the SLC
superfamily named SLC1 to SLC52, followed by the letter “A” as a space divider, then a
numeral for the individual members of the family (SLC10A1). Exceptions to this
nomenclature include SLC35 which uses other letters in addition to “A” to represent
different subfamilies (SLC35A, SLC35B), and the SLC21 family, which has been renamed
as SLCO to accommodate for easy organization and identification of the large number of
members within the family (7). There is a total of 395 individual members within the SLC
superfamily, which is far more expansive than the ABC superfamily (8). Over the last 2
decades, the discovery of expression cloning have allowed identification, and thus further
research on SLC transporters (9). A comprehensive list of all SLC transporters and their
clinical importance have all been reviewed by experts in the field (8). These SLC and ABC
transporters are expressed in all major organs of the body, including the liver, kidneys,
intestines, and blood-brain-barrier. Transporters that are critically important in
pharmacokinetics are located mainly at the sites of drug elimination, the liver and kidneys
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(2). One family of great importance is the SLC21 family, renamed to SLCO in 2003 due to
the rapid evolution of research on these transporters. This family encodes the protein family
organic anion transporting polypeptides (OATP), which have been extensively studied
because of their clinical and pharmacokinetic importance.

1.2 OATP
OATPs are a superfamily of membrane transporters that facilitate sodium-independent
uptake of a broad number of endogenous and exogenous amphipathic molecules. Today,
more than 300 members of the OATP family have been identified in several organisms
including humans, rats, mice, monkeys, pigs, and dogs (2). However, no OATP
homologues have been identified in bacteria or yeast. In humans, 11 members have been
identified and categorized into 6 families (OATP1-OATP6) based on more than 40%
sequence homology. Additional letters are added to further subdivide transporters that
share more than 60% sequence homology (OATP1A). Finally, another number is added to
represent the chronological order of discovery (OATP1A1) (2). The first OATP to be
discovered was rat OATP1A1 in 1994 (10), and the first human OATP discovered was
OATP1A2 in 1995 (11). OATPs all have 12 transmembrane domains with intracellular
termini, but differ in their substrate specificity and tissue distribution (2). Below is an
overview of all human members of the OATP family.

1.2.1

OATP1A2

OATP1A2 was cloned in 1995 and was the first human OATP discovered. It was found to
have 67% identical sequence compared to the previously characterized rat OATP1A1.
OATP1A2 was found to be expressed in the brain, lung, liver, kidney, intestine, and testes,
with particular strong expression in the brain. This suggests an importance in mediating
transport of drugs and hormones across the blood-brain barrier. Substrates for OATP1A2
include endogenous bile acids and steroid hormones as well as a broad spectrum of drugs
(2, 11).
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1.2.2

OATP1B1

OATP1B1 is a member of the OATP superfamily that is exclusively located on the
basolateral membrane of hepatocytes. It was the second human OATP to be characterized
and share 44% sequence identity with OATP1A2. It facilitates the hepatocellular uptake of
a variety of endogenous molecules to be metabolized in the liver (12). Complete deficiency
of OATP1B1 and a close family member OATP1B3 manifests as Rotor syndrome, an
autosomal recessive disorder characterized by hyperbilirubinemia and jaundice during
childhood, highlighting the significance of OATP1B1 in bilirubin transport. Patients with
Rotor syndrome, however, live normal lives with no clinical complications (13). OATP1B1
is also the transporter for many xenobiotics, most importantly statins (2). The role of
OATP1B1 as a drug transporter has been extensively studied, and the transporter’s function
has been associated with variability in patient sensitivity to these substrates. Changes in
the function of the transporter can lead to unpredicted outcomes in drug therapy, and even
cause severe adverse events (3). Due to this, OATP1B1 has been a focus in the field of
personalized medicine to predict optimal dosing for drugs that are substrates.

1.2.3

OATP1B3

OATP1B3 was cloned in 2000 and shares 87% sequence identity with OATP1B1 and 61%
with OATP1A2. Similar to OATP1B1, OATP1B3 is expressed highly, if not exclusively
in the liver (14). Due to a high degree of similarity between OATP1B1 and OATP1B3, it
is not surprising that they share many common substrates (2). However, there are also
substrates that are exclusively transported by one and not the other. Cholecystokinin-8
(CCK-8) is a substrate that is highly transported by OATP1B3 but not OATP1B1.
However, a study showed that by mutating 3 amino acid residues (A45G/L545S/T615I) in
OATP1B1 to the corresponding amino acids in OATP1B3, transport of CCK-8 was
attained in newly mutated OATP1B1. Conversely, mutating these 3 residues in OATP1B3
to the corresponding residues in OATP1B1 resulted in loss of CCK-8 transport (15). This
suggests that there are specific amino acids that dictate recognition or transport of a
particular substrate. The mutation of these 3 residues did not alter the transport of any other
substrates, suggesting that different substrates utilize different sites as recognition targets
(15).
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1.2.4

OATP1C1

OATP1C1 was the last member of the OATP1 family discovered, and was found to share
48% sequence identity with OATP1A2, 1B1 and 1B3. OATP1C1 highly and selective
transports thyroid hormones, specifically thyroxine, and is expressed bilocally in the brain
and testes, suggesting an importance of this transporter in the uptake and distribution of
iodothyronines in these organs (16). Compared to other members of the OATP1 family,
OATP1C1 has a much narrower list of endogenous and exogenous substrates, indicating
that it serves a specific function in the areas expressed rather than being a multipurpose
transporter (16). Genomic organization of OATP1C1, as well as the 3 other members of
the OATP1 family, are all clustered on chromosome 12p12. The sequence identity and
genomic organization of the 4 OATP1 members suggest that they likely evolved by gene
duplication from a common ancestor, and diverged to be expressed in different tissue to
serve different functions (16).

1.2.5

OATP1A2

OATP2A1 was cloned in 1996 from human kidney cDNA library, and was found to be a
high affinity prostaglandin transporter. Unlike members of the OATP1 family which are
highly expressed in certain tissue, OATP2A1 is ubiquitously expressed in almost every
tissue type (17). Recent studies in OATP2A1 revealed that it is a high affinity transporter
for latanoprost, the most commonly prescribe prostaglandin for the treatment of glaucoma.
Therefore, the function of OATP2A1 is important for the bioavailability of latanoprost in
antiglaucoma treatment (18). In addition to prostaglandins, OATP2A1 shares a few
common substrates with members of OATP1 family, but the true physiological
significance of OATP2A1 in areas other than the eye remain unknown (2).

1.2.6

OATP2B1, OATP3A1, OATP4A1

OATP2B1, 3A1, and 4A1 were discovered simultaneously in 2000. OATP2B1 has broad
tissue distribution with the highest expression in liver (19). OATP2B1, along with
OATP1B1 and OATP1B3 are the 3 known OATPs that mediate hepatocellular uptake of
substrates (1). Contrary to 1B1 and 1B3, OATP2B1 has limited substrate specificity, but
includes drugs in the statin class that are also substrates for OATP1B1 (2). OATP2B1 was
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shown to be expressed in muscle, and proposed to possibly mediate uptake of statins to the
muscle to cause the common adverse effect of statin-induced myopathy (20). In the
intestines, OATP2B1 was shown to mediate pH-dependent transport of pravastatin and
fexofenadine, which is a feature not seen with other OATPs (21).
OATP3A1 and 4A1 have not seen as much research focus as OATP2B1 since their
discovery. They are both ubiquitously expressed and share a similar list of substrates that
include estrone-3-sulfate (E1S) and prostaglandins (19). The physiological as well as
clinical role of these transporters are currently unknown as research interest has been
focused on other OATPs.

1.2.7

OATP4C1

OATP4C1 was characterized in 2004 and was found to be predominantly expressed in
kidney. Only a few substrates for OATP4C1 have been identified and include digoxin,
ouabain, and E1S (22). Interestingly, inhibitors that inhibited E1S uptake did not inhibit
digoxin uptake, suggesting that E1S and digoxin utilize different recognition sites for their
transport (23). This is consistent with the conclusions made in the OATP1B1-OATP1B3
mutagenesis study previously discussed.

1.2.8

OATP5A1, OATP6A1, and OATPs in cancer

OATP5A1 and 6A1 are the most recent and poorly understood members of the OATP
family. OATP5A1 was shown to be expressed predominantly in breast tissue (24), and
OATP6A1 predominantly in testes (25). Endogenous substrates and physiological function
of these transporters are also unknown. However, they have been discussed in their
potential role as targets for cancer therapy, along with many other OATPs. In addition to
the physiological expression of OATPs in various tissue, all 11 human OATPs have been
shown to be expressed in various tumours (26). Many anti-tumour agents used today have
also been shown to be substrates for various OATPs. This makes OATPs an attractive
target for selective uptake of anti-tumour drugs into tumour cells. The expression of
OATPs in tumour cells and the regulation of hormones by various OATPs, together with
their involvement in hepatocellular uptake of several anti-tumour drugs, makes full
understanding of all OATPs an essential task for outlining intricate pathways for
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chemotherapeutic drug targeting (27). This has been an emerging field of research and
could potentially result in significant progress in tumour targeting and treatment.

1.2.9

Factors affecting OATP regulation and function

Regulation of OATP expression have been shown to occur at the transcriptional and posttranslational levels. Several nuclear receptors such as hepatocyte nuclear factor 4α
(HNF4α), liver receptor α (LXRα), and farnesoid X receptor (FXR) have been shown to
regulate the liver-specific OATP1B1 (28). Additionally, HNF1α and FXR have both been
shown to also regulate OATP1B3 (29). These nuclear receptors, when activated, bind to
response elements located in the 5’ untranslated region to regulate transcription. Ligands
that activate these nuclear receptors also in turn enhance OATP expression and overall
transport activity (2).
Post-translational regulation is also observed in OATPs. Glycosylation is a major posttranslational modification in most membrane proteins and was proposed to regulate
membrane targeting and protein stability. N-glycosylation sites on extracellular loops 2
and 5 are common features among OATPs (2). A study found that 3 asparagine residues at
positions 134, 516, and 503 in OATP1B1 are glycosylated, and when simultaneously
mutated to glutamine, glycosylation was prevented which resulted in significantly
decreased OATP1B1 expression and transport activity (30).
The classes of drug transporters previously discussed have significant physiological
contributions, but the true interest lies in their ability to transport and facilitate distribution
of drugs. Due to the transporters’ involvement in drug absorption, distribution, and
elimination, interindividual variability in transporter function has been shown to be one of
the causes for the variability observed in drug response (31). Transporters may be induced,
inhibited, or have altered function due to genetic differences, and any of these changes can
lead to unpredicted outcomes in drug therapy. The field of inherited differences in drug
response, pharmacogenomics, has seen significant growth over the last decade since the
publication of the human genome project. It is now widely accepted that drug metabolizing
enzymes and drug transporters can possess genetic differences that lead to changes in
protein function, and ultimately a difference in bioavailability and response to drugs (32).
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1.3 Single nucleotide polymorphism
The most common form genetic variation that can affect protein function are SNPs. SNPs
are defined as a change in one nucleotide in the gene that is observed in more than 1% of
the population, and can be synonymous or non-synonymous. Any protein involved in the
pathway of a drug is subject to polymorphisms, and thus may be a factor in determining
altered drug response (31). Traditional approaches to drug therapy have been trial-anderror and one-size-fits-all. With the trial-and-error approach, an initial safe dose is given
and titrated upwards until optimal treatment is obtained. This method is safe but requires
time between initiation of treatment and reception of efficacious results. This length of time
is crucial and may not be available with certain conditions or individuals. The one-sizefits-all approach treats the population as an average individual, and an average safe dose
determined in large scale clinical trials are given to everyone in the population (33).
However, interindividual variability is always observed with individuals that respond
poorly or do not respond to the treatment. Due to growing understanding of the human
genome and interest in genetic differences in drug metabolizing enzymes and transporters,
personalized medicine has emerged as a new approach to drug therapy in hopes to predetermine optimal choice of therapy and dose for each individual to minimize adverse
reactions and maximize therapeutic efficacy (31).

1.4 SNPs in drug metabolizing enzymes and drug
transporters
Initial studies in pharmacogenomics primarily focused on drug metabolizing enzyme
cytochrome P450s (CYPs). There have been more than 50 CYP enzymes characterized,
but a few of them, primarily CYP1A2, 3A4, 3A5, 2C9, and 2C19, metabolize more than
90% of all drugs on the market today. Thus it is not surprising that tremendous research
has been placed on these enzymes and the genetic variations that exist in them (33). Many
SNPs as well as other types of genetic variation such as copy number mutations were
characterized, and the effects of these genetic differences on CYP enzyme function were
determined by plasma drug or metabolite concentrations as well as phenotypic observations
in drug response. For many of these enzymes, genetic variations have been determined to
categorize individuals as poor, intermediate, extensive, or ultra-rapid metabolizers
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depending on a SNP or a combination of SNPs. With this knowledge, drugs that are
substrates for a specific CYP enzyme can be dosed according to an individual’s CYP
genotype to enhance clinical outcomes (33).
Due to complex interplay of proteins in drug absorption, distribution, metabolism, and
elimination, knowledge of SNPs in CYP enzymes have been beneficial, but not absolute in
guiding drug choice and dosage. Drug transporters are also significantly involved the
pharmacokinetic pathway, and rapid evolution of drug transporter research in the 1990s
and 2000s led to increased interest in genetic variations in these transporters (3). Both the
ABC superfamily and SLC superfamily have numerous members that contain SNPs that
affect transport function in vitro as well as drug concentrations in vivo. Most clinically
significant transporters are located in the liver and the kidney, since these are major sites
of drug metabolism and elimination, and transport of drug in and out of these organs have
great impact on drug bioavailability and response (34). Figure 1 shows the major
transporters expressed in the liver and kidneys with known SNPs that affect plasma drug
concentrations and subsequently drug response.

1.4.1

P-gp

P-glycoprotein (P-gp; MDR1; gene symbol ABCB1) was the first drug transporter to be
discovered, thus it is not surprising that over 1000 SNPs have been characterized in the
gene (35). P-gp is an efflux transporter and contributes to the elimination of toxic
compounds and xenobiotics and is located at several major organ systems including the
intestines, liver, kidney, and the bood-brain barrier. P-gp also has an incredibly broad
substrate specificity, further demonstrating the importance of P-gp in pharmacokinetics.
The most frequently studied SNP is ABCB1 3435C>T (rs1045642), a synonymous SNP
located in exon 26 with high frequencies observed across all ethnicities (36). Several
studies have examined the functional consequences of this SNP, including its effects on
mRNA and protein levels and transport of several substrates. Initial studies found this SNP
to be associated with decreased intestinal expression leading to significantly higher plasma
levels of digoxin (37). However, contradictory results have since been shown and the exact
outcome of C3435T in vitro remains unknown (36). Since several classes of drugs are
substrates for P-gp, attempts have been made to correlate SNPs with therapeutic outcomes.

10

Figure 1. Human drug transporters with SNPs that may contribute to interindividual
variability in pharmacokinetics.
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A study looked at the treatment responsiveness of anticonvulsants in epilepsy and found
the C3435T SNP to be associated with better drug response (38). This could possibly be
due to lowered expression at the blood-brain barrier resulting in decreased drug excretion,
but has not been confirmed by functional studies. Several studies later identified both
similar and contradictory results, and meta-analyses summarized no significant association
between any ABCB1 SNPs and anticonvulsant treatment outcome (39).
Opioids are another major class of drugs that are substrates for P-gp. Multiple studies were
in agreement with their results showing that patients who are homozygous variant for
C3435T SNP required lower opioid dosage and had greater pain relief compared to
wildtype individuals (40, 41).
The effect of ABCB1 SNPs in anti-cancer therapy has also been a target of investigation.
Studies involving patients with leukemia were again inconsistent with some studies
showing a link between clinical outcomes and C3435T genotype and other studies showing
no association. The studies that found an association were also contradictory, where some
studies found 3435CC to have better outcomes and others found 3435TT to be beneficial
(42, 43). The variability of results show that there is not a significant association between
ABCB1 SNPs and anti-leukemia treatment.
Although numerous studies have attempted to find significance in ABCB1 SNPs, the
overall picture is that there is no clear association between genotype and treatment outcome
with P-gp substrate drugs. However P-gp continues to be of interest due to its broad
substrate specificity and expression, and it has been suggested that SNPs may be more
involved in mediating and altering drug-induction, inhibition, and drug-drug interaction at
the transporter.

1.4.2

BCRP

Breast cancer resistance protein (BCRP; gene symbol ABCG2) is another prominent efflux
transporter involved in chemoresistance. It was found to have broad expression including
the intestines, bile canaliculi, mammary glands, and blood-brain barrier (44). BCRP
expression is increased in the mammary glands during lactation, possibly facilitating the
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secretion of vitamins and other nutrients into breast milk (45). Pharmacologically, BCRP
also has a very broad range of drugs as substrates, most of which are anti-cancer drugs
(35).
The most frequently studied SNPs in BCRP are 34G>A (rs2231137) and 421C>A
(rs2231142), both with high minor allele frequencies (MAFs) of around 10% (35). These
SNPs have had numerous in vitro and clinical studies done. One in vitro study investigating
G34A and C421A found that they were both associated with decreased transport of
indolocarbazoles mediated by decreased Vmax, increased Km, and decreased expression
(46). Another study using E1S as substrate found similar results with C421A, but no change
in transport with G34A (47). Additional studies on these SNPs confirmed C421A as a lossof-function polymorphism, but the effects of G34A are still inconclusive.
In vivo studies correlating BCRP genotype with plasma drug concentrations also focused
on the two SNPs described. There have been a wide number of studies investigating anticancer drugs including camptothecins and tyrosine kinase inhibitors (TKIs). The
camptothecins diflomotecan, topotecan, and irinotecan metabolite SN-38 are all known
substrates for BCRP. Patients that are carriers for C421A SNP exhibited higher plasma
concentrations of both diflomotecan and toptecan, but not irinotecan or SN-38 (48-50).
This is possibly due to the more complex pharmacokinetic pathway that irinotecan
undergoes. There were no association between camptothecin levels and G34A genotype.
Studies involving tyrosine kinase inhibitors all found no association between G34A/C421A
and AUC. However, two other SNPs, C-15622T and C1143T, emerged and were
associated with increase severity of side effects following TKI therapy, suggesting
prolonged system exposure to the drug (51).
Statins are another major class of drugs transported by BCRP. Higher plasma levels of
rosuvastatin in carriers of C421A has been shown in multiple studies (52, 53), and it has
also been observed that C421A associated with greater reduction in LDL-C following
rosuvastatin therapy (54). Additionally, atorvastatin and fluvastatin plasma levels have also
been correlated with C421A SNP, though not as significant as rosuvastatin (53). The
increased plasma concentration and efficacy is likely due to decreased activity of the
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transporter leading to increased absorption to the blood and liver. Other statins pitavastatin
and pravastatin did not show any correlation with BCRP SNPs, and the reason for this lack
of association is currently unknown and attributed somewhat to compensatory mechanisms
(53, 55).
BCRP, like P-gp, has very broad tissue distribution and substrate specificity. The SNP
C421A seemed to be the most significant SNP in terms of pharmacokinetics camptothecins
and statins, but the effects of G34A were not as conclusive. The overall impact of BCRP
SNPs on pharmacokinetics appeared to be minor and does not justify pharmacogenomicsguided dosing and selection. However, only a few SNPs have been studied in clinical
settings, so there is definitely a large area of unknown in BCRP pharmacogenomics that
have yet to be explored.

1.4.3

MRPs

Multidrug resistance-associated proteins (MRPs; gene family ABCC) are another class of
highly polymorphic efflux drug transporters primarily located in the liver, kidneys, and
intestines (35). MRP2 and 8 (ABCC2, ABCC11) have been extensively studied for their
polymorphisms and clinical effects. Interestingly, MRP1 was the second transporter
discovered after P-gp, but studies regarding polymorphisms in this transporter have not
been as comprehensive. In vitro functional studies of MRP1 SNPs found 1299G>T
(rs60782127) to be associated with decreased transport of estradiol-17-β-D-glucuronide
(E217βG), but was also associated with increased doxorubicin resistance, demonstrating
substrate specific effects. The SNP 2965G>A (rs35529209) also showed significant
reduction in E217βG transport (56). Clinical studies correlating MRP1 SNPs to drug
treatment outcomes have also been unconvincing, and the SNPs discovered do not coincide
with any of the SNPs with significant in vitro effects (57).
MRP2 arose as a protein of interest due to the discovery that genetic variants in MRP2
resulting in a loss-of-function protein results in the hereditary disorder Dubin-Johnson
syndrome, characterized by conjugated hyperbilirubinemia (58). MRP2 secretes
conjugated bilirubin from liver into bile, and the loss of function mutant is compensated
by secretion of conjugated bilirubin into blood by MRP3, resulting in hyperbilirubinemia
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(59). Clinically, one MRP2 SNP, -24C>T, had high frequencies and was associated with
decreased clearance of substrate drugs mycophenoloic acid and methotrexate (60, 61).
MRP8 SNPs have also been studied in detail. This was because the SNP 538G>A
(rs17822931) was found to determine wet/dry earwax type (62). It was the first time that a
single allele was discovered to correspond to a specific physical trait. In addition to
dictating earwax type, G538A SNP has also been associated with axillary osmidrosis.
Carriers of the G allele were found to have larger apocrine glands, thus secreting more
preodoriferous compounds (63). Clinically, this SNP has been investigated in relation to
breast cancer risk and anti-cancer drug resistance. However, no significant associations
have been discovered with any of the drug investigated, and it remains to be seen if G538A
allele is pharmacologically significant (64).

1.4.4

OCTs

Organic cation transporters (OCTs; gene family SLC22) are uptake transporter expressed
in many tissues in the body. There are 3 members in the family, OCT1, 2, and 3 (SLC22A1,
2, 3). OCT1 is primarily expressed in liver while OCT2 is primarily expressed in the
kidneys. OCT3 seemed to show a more ubiquitous expression throught various tissues (35).
A broad range of substrates have been found for OCTs, and SNPs in OCTs have been
investigated for clinical effects. Most studies OCT SNPs have focused on the drug
metformin, which has been shown as a substrate for all 3 members, but detailed clinical
studies have only been completed for OCT1 and 2.
There has been many SNPs identified in OCT1, and many have demonstrated reduced in
vitro uptake of prototypical OCT substrates MPP+ and TEA as well as metformin (65).
However, the majority of the polymorphisms discovered were quite rare and the effects
were only observed by single studies. The SNPs with higher frequencies did not affect
MPP+ or metformin transport. Divergent results have been found in studies correlating
SNPs with metformin plasma concentrations and clinical outcome (66, 67). Combinations
of SNPs seemed to have amplified effect on metformin renal clearance and plasma glucose
levels, and has yet been verified (68). Despite the inconsistent results, OCT1 genotype may
still play an important role in understanding the variability in metformin therapy.
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Significantly less SNPs have been identified for OCT2. One SNP, 808G>T (rs316019), has
fairly high frequencies across all ethnic groups and has been investigated in many studies
to be a reduced function polymorphism. Patients that carry the G808T variant allele
exhibited higher plasma concentrations of metformin due to decreased renal clearance (69).
Although rare, SNPs in OCT1 and OCT2 definitely affect transport in vitro. Whether their
impact on metformin pharmacokinetics is significant enough to warrant genotyping for
patients has yet to be seen. Further research needs to be done to fully understand the
contribution of OCTs in OCT substrate pharmacokinetics.

1.4.5

OATs

Organic anion transporters (OATs) also belong to the gene family SLC22, and the 3
members OAT1/2/3 are given the gene names SLC22A6/7/8. OATs are primarily expressed
in kidneys and are transporters for a number of drugs (35). Polymorphisms in OATs have
not been extensively studied, and there has been very minimal genetic variation seen in
OAT2 (70). Rare SNPs have been identified in OAT1 and OAT3, and studies have
attempted to correlate OAT genotype with diuretics and antiviral drugs. The results
however show no correlation, possibly due to low patient population or the rescuing of a
deficient polymorphism by other members of the family (35). The role of genetics in OATs
remain unclear and more studies are necessary for a better understanding of the effects of
OAT genotypes.

1.4.6

OATPs

OATP1A2, OATP2B1, OATP1B3, and OATP1B1 are 4 members of the OATP family that
have been studied for genetic polymorphisms. Studies involving OATP1A2, 2B1, and 1B3
have been fairly inconsistent, and polymorphisms in these 3 transporters seemed to play a
small role in substrate drug pharmacokinetics (35). Studies in OATP1A2 have attempted
to correlate known SNPs with lopinavir and imatinib, but found no association (71, 72).
OATP1B3 522G>C SNP seemed to facilitate substrate dependent changes in transport
activity, while other identified SNPs in the same study did not show functional effects (73).
In vitro studies in OATP2B1 found the *3 variant to be a significant loss-of-function
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polymorphism when transporting E1S (74), and the SNP 1457C>T was associated with
decreased fexofenadine transport (75).
By far the most clinically significant and widely studied transporter is OATP1B1, a liverspecific member of the OATP family. SNPs in OATP1B1 have been shown to functionally
affect transporter activity in vitro and in vivo, and significantly affect plasma
concentrations of substrate drugs, which include several widely prescribed medications.
This allowed the acknowledgement of the potential benefits of genotype-guided dosing and
the advancement of personalized medicine. The effects of OATP1B1 polymorphisms are
described in detail in the section below.

1.4.7

OATP1B1

OATP1B1, described previously, is a 12 transmembrane uptake transporter located on the
basolateral membrane of human hepatocytes. Figure 2 shows the predicted topology of
OATP1B1 and some of the important SNPs discovered. Functional SNPs in OATP1B1
were first characterized in 2001. 16 variants of OATP1B1 were identified, and 7 of these
variants were found to have altered transport of in vitro probes E1S and E217βG compared
to wildtype. The changes in transport were mediated by a combination of decreased affinity
between substrate and transporter, and decreased maximum transport velocity which could
be explained by a decrease in total cell surface expression of the transporter (76). Among
the SNPs identified were SLCO1B1*1b (c.388A>G; rs2308283), *5 (c.521T>C;
rs4149056), and *15 (*1b + *5), which have all since been extensively studied in vitro and
in vivo. SLCO1B1*1b is listed to have a MAF of 0.4050, and SLCO1B1*5 has a MAF of
0.1230 according to NCBI’s SNP database (dbSNP). Due to high frequencies in the
population, effects caused by these SNPs would affect a large number of patients.
SLCO1B1*1b was found not to affect the transport of E1S, E217βG, and rosuvastatin in
vitro (76), and in vivo studies show no association with plasma concentrations of
pravastatin and rosuvastatin (77). Other studies of SLCO1B1*1b however showed that this
SNP increased OATP1B1 function and was associated with increased transport of E1S and
E217βG and decreased plasma levels of pravastatin (78, 79). The disparity between studies
suggest that SLCO1B1*1b likely does not have a major impact on transport function.
SLCO1B1*5 and *15 were both found to decrease the transport of most statins and other
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Figure 2. Predicted 12-transmembrane topology of OATP1B1 and some significant
SNPs that have been discovered.
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substrates in vitro (76, 80). In vivo studies found an increase in AUC and Cmax of these
substrates (81-83). A genome-wide association study on more than 300 000 markers found
SLCO1B1*5 to be the only SNP linked with simvastatin-induced muscle toxicity (84). Due
to these studies, SLCO1B1*5 and other haplotypes containing this SNP can significantly
affect plasma statin levels, and dosing of statins may be adjusted if the patient was found
to be a carrier for this SNP (52).
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Chapter 2

2

« Objectives and Aims »

2.1 Rationale
The primary class of drugs that are substrates for OATP1B1 are statins, which are drugs
used to reduce cholesterol and LDL to decrease risk for cardiovascular disease (34). Its
therapeutic effects are profound, but adverse reactions are seen in some patients.
Cholesterol synthesis primarily takes place in the liver and begins with the combination of
3 acetyl-CoA molecules to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). HMGCoA is then reduced by HMG-CoA reductase into mevalonate, which is the rate-limiting
step of the cholesterol synthesis pathway. Mevalonate then undergoes a long series of
reactions to form cholesterol. Statins lower cholesterol by inhibiting HMG-CoA reductase,
preventing the formation of mevalonate and ultimately cholesterol (85). Since the majority
of cholesterol is synthesized in the liver, successful uptake of statins into hepatocytes are
important not only for it to exert its effect in the liver, but also to reduce toxicities
associated with prolonged systemic exposure (32). The most common side effect of statin
therapy is myalgia and myopathy, and patients experiencing these side effects will often
recover once statin therapy is terminated. In a very small number of patients, the effect can
develop into a fatal condition rhabdomyolysis, the total breakdown of muscle tissue. The
cause of this side effect is unknown, and different mechanisms have been proposed and
have yet been absolutely verified (86). Risk factors for myopathy include advanced age,
low BMI, female gender, Asian origin, and the existence of systemic disease involving
renal or liver complications (87). A common characteristic among patients experiencing
statin-induced muscle toxicity is elevated concentrations of statins in blood (88). Since
SLCO1B1*5 allele has been shown to be associated with increased plasma concentrations
of almost all statins, patients that are carriers for variant alleles are more susceptible to
statin-induced muscle toxicity and should be monitored carefully if on statin therapy (31).
Although studies unanimously agree that SLCO1B1*5 allele contributes to significant loss
of function of the transporter and elevated plasma concentrations of statins, attempts at
showing correlation between *5 genotype and clinical outcome of statin therapy have been
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inconsistent. Due to a tremendous amount of SNPs that have been discovered in OATP1B1,
the possibility exists that other SNPs may also affect the function of OATP1B1.
Six non-synonymous SNPs in OATP1B1 were chosen to be analyzed in vitro. Due to lack
of murine model of OATP1B1, in vitro functional studies are the best predictors of how
SNPs can affect the transporter in vivo (3). These 6 SNPs were found on dbSNP which
collects new and seldom-studied SNPs from a wide range of sources. Three criteria were
developed to select for SNPs that were most likely to have significant functional
consequences. The first criterion was MAF. A higher MAF indicates a greater number of
carriers in the population and greater potential for clinical significance if the SNP was
found to be functional. The next criterion was the position of the SNP in the transporter. It
has been demonstrated in previous studies that SNPs in the transmembrane and
extracellular regions of the transporter were more likely to lead to functional consequences.
Transmembrane domains 8 and 9, as well as extracellular loops 2 and 5 have all been
suggested as important regions for substrate binding and transport (89, 90). Therefore only
SNPs in the transmembrane and extracellular domains were considered. Lastly, the
resultant amino acid change caused by the SNP was taken into account. If the amino acids
before and after the polymorphism had drastically different side chains, it would be more
likely to affect the overall folding of the protein and more likely to affect substrate binding,
transport, and other interactions. With these criteria, the SNPs c.298G>A (rs144508550,
Gly100→Ser), c.419C>T (rs147450830, Ser140→Phe), c. 463C>A (*4, rs11045819,
Pro155→Thr), c.1007C>G (rs72559747, Pro336→Arg), c.1463G>C (*9, rs59502379,
Gly488→Ala), and c.1738C>T (rs71581941, Arg580→Stop) were chosen to be
functionally characterized (Table 1). Of these 6 SNPs, *4, *9, and C1007G have been
studied previously. SLCO1B1*4 was found to not significantly affect the uptake of E1S and
E217G, while SLCO1B1*9 was found to nearly abolish OATP1B1 uptake of rosuvastatin
(76). SLCO1B1*4 has also been studied in vivo and was found to be correlated with lower
atorvastatin AUC (91). C1007G was also found to not have any significant effects on
OATP1B1 transport (92). The other 3 SNPs G298A, C419T, and C1738T have never been
studied before and will be characterized for the first time.
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2.2 Objectives
This study seeks to confirm previous in vitro data on SLCO1B1*4, *9, and C1007G, as
well as functionally characterize the new SNPs G298A, C419T, and C1738T using
substrates E1S, E217βG, and rosuvastatin. Subsequently, these SNPs will be studied in vivo
by genotyping patients on rosuvastatin and determining any associations between plasma
statin concentrations and genotype. This would contribute to the database of known
functional OATP1B1 polymorphisms, as well as determine new pharmacogenomics
predictors of plasma statin levels. With this information, patients starting rosuvastatin
could be genotyped for these functional SNPs and be dosed accordingly to minimize the
chance of adverse reactions.

2.3 Hypothesis
We predict that OATP1B1 containing the SNPs to be investigated will have decreased
total uptake of all 3 substrates compared to wildtype facilitated by lower Vmax, higher Km,
and lower cell-surface expression. Due to impaired function of the transporter, patients
carrying these SNPs will be associated with higher plasma concentrations of rosuvastatin
due to reduced hepatic uptake of statins compared to wildtype individuals.

Table 1. SNPs chosen to be functionally analyzed in this study.
dbSNP rs #

Nucleotide

Amino Acid

Domain

MAF

rs144508550

G298A

G100S

3rd TM

N/A

rs147450830

C419T

S140F

2nd EX

N/A

rs11045819

C463A

P155T

2nd EX

0.078

rs72559747

C1007G

P336R

7th TM

0.001

rs59502379

G1463C

G488A

5th EX

0.01

rs71581941

C1738T

R580Stop

11th TM

0.005
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Chapter 3

3

« Methods »

3.1 Materials
Radiolabelled [H3]-E1S (45 Ci/mmol, >97% radiochemical purity) and [H3]-E217βG (34.3
Ci/mmol, >97% radiochemical purity) were purchased from Perkin Elmer, and
radiolabelled [H3]-rosuvastatin (74 Ci/mmol, 97.1% radiochemical purity) was purchased
from GE Healthcare. Unlabelled E1S sodium salt and E217βG sodium salt were purchased
from Sigma-Alridch, and unlabelled rosuvastatin calcium was purchased from Toronto
Research Chemicals. SLCO1B1*1a cDNA packaged in pEF-V5-His-Topo expression
vector was provided by Dr. Kim. Custom rabbit OATP1B1 polyclonal antibody were
developed by Research Genetics (Huntsville, AL), and was raised against C-terminal
peptide of OATP1B1 (ESLNKNKHFVPSAGADSETHC). Actin antibody HRP conjugate
was purchased from Santa Cruz Biotechnology, rabbit polyclonal calnexin antibody was
purchased from Cedarlane Labs, and mouse monoclonal Na+/K+-ATPase antibody was
purchased from Axxora. Rosuvastatin patient plasma levels were measured by Dr.
Marianne DeGorter, and purified patient DNA were provided by Dr. Kim at 10 ng/µL. All
dry ingredients used in buffers were purchased from Sigma-Alridch of the highest quality.

3.2 Cell culture
Cell types used were HeLa, HEK293, and HEK293A. Media used for all cell culture was
Dulbecco’s Modified Eagle Medium (DMEM, Gibco) containing fetal bovine serum, Lglutamine, and penicillin/streptavidin. Cells were incubated at 37 °C and 5% CO2. Viral
cell culture were incubated in a separate designated viral incubator in the same conditions.
Media was replaced every 2 days, and cells were trypsinized and replated before reaching
confluency. When plating cells for experiments, cells were trypsinized and pelleted by
centrifugation at 1000 rpm for 3 min. Media and trypsin were removed and the pellet was
resuspended in fresh media. Cell number was counted on a haemocytometer and the
appropriate number of cells was plated for experiments.
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3.3 Introducing SNPs in SLCO1B1
SNPs were introduced to SLCO1B1*1a plasmid expressed in pEF-V5-His-Topo using
QuickChange Site-directed Mutagenesis as per manufacturer’s protocol. Mutated plasmids
were transformed to XL10-Gold Ultracompetent Cells, plated on LB-Ampicillin agar
plates and incubated overnight at 37 °C. The following day, plasmids were extracted from
6 separate colonies using QIAprep® Spin Miniprep Kit. Successful mutagenesis for
variants G298A, C419T, and C463A (*4) were confirmed by sequencing with T7 promoter.
Successful mutagenesis for variants C1007G, G1463C (*9), and C1738T were confirmed
by sequencing with custom primers. In addition to generating SLCO1B1 variants, sitedirected mutagenesis was used again to remove a Pac-I digestion site in SLCO1B1. Pac-I
digestion is an essential step for further propagation of adenovirus in cells, so Pac-I sites
within SLCO1B1 must be removed. The SNP C419T is located close to the Pac-I site, so a
separate mutagenesis primer was required to mutate the Pac-I site as well as maintain the
C419T SNP. All mutagenesis and sequencing primers used are listed in Tables 2 and 3.

3.4 Expression of OATP1B1 variants as adenovirus
OATP1B1 wildtype and variants were expressed using ViraPower Adenoviral Expression
System (Invitrogen). SLCO1B1*1a and variant DNA were isolated from pEF vector by
digestion with KpnI and NotI (New England Biolabs), followed by separation by gel
electrophoresis and purification of the ~2000 bp band. pENTR1A dual selection vector was
also digested with KpnI and NotI and separated by gel electrophoresis and a different
~2000 bp band was isolated from the gel. SLCO1B1 entry clone was generated by ligating
isolated SLCO1B1 DNA to digested pENTR1A vector using T4 DNA ligase with
OATP1B1 DNA to pENTR1A DNA ratio of 10:1. Ligated product were transformed to
One Shot® TOP10 Chemically Competent E. coli and plated on LB-Kanamycin agar
plates. 6 colonies were selected following overnight incubation at 37 °C, and plasmids were
purified again with QIAgen miniprp kit. Correct insertion of SLCO1B1 into pENTR1A
dual selection vector was verified by digestion with BamHI restriction enzyme. Plasmids
with a 313 bps digestion product were selected for further propagation in adenoviral
plasmid. Selected SLCO1B1 entry clones were then recombined with pAd/CMV/V5-DEST
vector as per manufacturer’s protocol, transformed to One Shot® TOP10
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Table 2. Mutagenesis primers.
Primer

Sequence

Length

Tm (°C)

G298A

5’-ATAGACCAAAGTTAATTGGAAT

47

67.3

45

65.6

39

68.9

47

67.3

35

70.5

35

69.4

26

66.6

26

66.8

CAGTTGTTTCATTATGGGAATTGGA-3’
C419T

5’-CATCAGAAAATTCAACATCGA
CCTTATTCACTTGTTTAATTAATC-3’

C463A

5’-ATCACTCAATAGAGCATCAACT
GAGATAGTGGGAAAAGG-3’

C1007G

5’-TTTTAAAAGCATCCTTACTAATC
GCCTGTATGTTATGTTTGTGCTTT-3’

G1463C

5’-CTCACCCTGTCTAGCA
GCTTGCAAATCTTCAAGTG-3’

C1738T

5’-GGGTTTCCACTCAATGGTT
ATATGAGCACTAGGAG-3’

PacI

5’-CATCGACCTTATC
AATTTTATCACTC-3’

C419T-PacI

5’-AAAATTCAACAT
CATCACTCAATAGA-3’
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Table 3. Sequencing primers.
Primer

Sequence

Length

Tm
(°C)

Forward Primer 1

5’-GGAAGCTTTGAAATTGGAAA-3’

20

54.2

Forward Primer 2

5’-ATTCAACATCGACCTTATCC-3’

20

56.3

Forward Primer 3

5’-AAGTCAATGGGAACCAGTCT-3’

20

58.4

Reverse Primer 1

5’-CCAGATTCCTTTAAACAACC-3’

20

56.3

Reverse Primer 2

5’-TAAGGATGCTTTTAAAAGAC-3’

20

52.2
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Chemically Competent E. coli and plated on LB-Ampicillin plates to generate adenoviral
expression clones. GenElute™ HP Plasmid Maxiprep Kit was used to isolate plasmids
from 3 separate clones and successful recombination was verified by digest with SpeI
forming a 735 bp product. After confirmation of recombination with SpeI, 10 µg of
adenoviral plasmid DNA were digested with PacI and purified with QIAquick® PCR
Purification Kit. 1 µg of PacI digested adenoviral plasmid DNA were then transfected to
HEK293A cells using Lipofectamine 2000 following manufacturer’s instructions to
produce crude adenoviral stock containing OATP1B1 wildtype and variant genes.

3.5 Purification of adenovirus from crude stock
Crude adenovirus stock generated from ViraPower Adenoviral Expression System
protocol was purified to increase virus concentration and reduce toxic cellular by-products.
HEK293A cells were grown to confluency on 150 mm tissue culture plates, then
transduced with 100 µL of crude adenovirus for 2-3 days until cells are noticeably filled
with virus. Cells were washed off and resuspended in 10 mM Tris at pH 9, then
homogonized in a dounce homogonizer. The solution was then spun at 1500 g for 5 min,
and 1.5 mL of the supernatant was layered on top of 3 mL of 10 mM Tris containing 36%
sucrose in an ultracentrifuge tube and spun at 100 000 g for 1 hour. Supernatant was then
removed, and the pellet was resuspended in 1 mL of 10 mM Tris as purified adenovirus.
Purified adenovirus concentration was determined with Adeno-X Rapid Titer kit following
manufacturer’s protocol.

3.6 Transduction of adenovirus in HeLa cells
HeLa cells were chosen to be transduced with SLCO1B1 adenovirus because they are a
stable adherent mammalian cell line that does not express OATP1B1. On day 1, appropriate
number of HeLa cells were plated and incubated overnight at 37 °C and 5% CO2 until cells
attached. On day 2, the media was removed and replaced with media containing adenovirus
at MOI of 1000. Cells were incubated with viral media overnight. The next day, viral media
was removed and replaced with fresh media and incubated overnight again. On day 4, cells
were stably overexpressing the transporter and ready for experiments. Table 4 lists the
number of cells and volume of media used for different types of plates.
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Table 4. Amount of cells plated for different sized plates.
Plate

# of cells to plate

Volume of media (mL)

6-well

500 000

2

12-well

200 000

1

24-well

100 000

0.5

96-well

10 000

0.2
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3.7 MTT assay to determine cell viability after adenoviral
transduction
HeLa cells were plated in 96-well plate and transduced with virus according to the protocol
above. On day 4 of transduction, 20 µL of Thiazolyl Blue Tetrazolium Bromide (MTT) at
5 mg/mL dissolved in PBS was added to each well. The plate was shaken for 5 min at 150
rpm and incubated at 37 °C and 5% CO2 for 4 hours to allow MTT to be metabolized to
formazan. Residual media was removed and the formazan formed was resuspended with
200 µL of DMSO and shook for 5 min. Optical density of each well was read at 560 nm
and subtracted background readings at 670 nm. Cells transduced with adenovirus were
compared to non-viral controls and expressed as a percentage. Each variant was performed
in triplicate and repeated on 2 separate days.

3.8 Functional studies of OATP1B1 variants
HeLa cells were plated and transduced with adenovirus following the protocol previously
described. On day 4, cells were washed with Krebs Henseleit Bicarbonate (KHB) buffer
(1.2 mM MgSO4, 0.96 mM KH2PO4, 4.83 mM KCl, 118 mM NaCl, 1.53 mM CaCl2, 23.8
mM NaHCO3, 12.5 mM HEPES, 5 mM glucose, pH 7.4), and allowed to equilibrate to 37
°C in the incubator. Transport was initiated by replacing KHB buffer with KHB buffer
containing radiolabelled and un-labelled substrates at various concentrations and incubated
for various periods of time depending on substrate and experiment. Un-labelled substrate
was used to acquire the desired drug concentration and minimal radiolabelled substrate was
used to achieve detection. After incubation with substrates, cells were washed 3 times with
ice-cold PBS and harvested in 500 µL of 1% SDS. Radioactivity was measured by TriCarb 2900TR Liquid Scintillation Analyzer (PerkinElmer) and protein content was
measured with BCA Protein Assay Kit (Thermo).
For time-dependent uptake studies, cells transduced with Lac Z and OATP1B1*1a
adenovirus were incubated with E1S, E217βG, or rosuvastatin at 100 nM for 3, 5, 10, 15,
20, and 30 min. Phase of linear active transport was determined to occur at 3 min.
For total uptake studies, cells transduced with OATP1B1*1a and variants were incubated
with substrates at 100 nM for 3 min.
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For concentration-dependent uptake studies, cells expressing OATP1B1*1a and variants
were incubated with substrates at varying concentrations for 3 min. E1S concentrations
used were 0.1, 0.5, 1, 2, and 5 µM; E217βG concentrations used were 0.1, 1, 5, 10, and 20
µM; rosuvastatin concentrations used were also 0.1, 1, 5, 10, and 20 µM. Concentrations
beyond the maximum concentrations used were determined to be toxic. All transport
experiments were done in triplicates on at least 3 different days.

3.9 Immunoblots to determine total cellular OATP1B1
expression
HeLa cells were grown and transduced with Lac Z and OATP1B1 wildtype and mutant
adenovirus as described above. For total cell lysate immunoblots, cells were scraped off
with PBS, spun at 500 g for 3 min, and resuspended in lysis buffer (5 mM Tris-HCl, 1%
Triton-X-100, 150 mM NaCl, 5 mM EDTA, protease inhibitor (Sigma)). Protein
concentrations were determined with BCA Protein Assay Kit (Table 5) and 20 µg of protein
from each OATP1B1 variant was analyzed. All reagents and equipment used in
immunoblots were purchased from Novex by Life Technologies. Samples were then mixed
with NuPAGE® LDS Sample Buffer and reducing agent 2-mercaptoethanol and incubated
at 70 °C for 10 min to linearize protein. Gel electrophoresis was ran on NuPAGE® 4-12%
Bis-Tris Protein Gels in X-Cell SureLock™ Mini-Cell Apparatus with NuPAGE® MES
SDS Running Buffer. Electrophoresis was done at constant voltage of 200 V until protein
has run through the gel. After gel electrophoresis, proteins were blotted onto nitrocellulose
membranes with 0.45 µm pores. Blotting was performed with X-Cell II™ Blot Module and
the gels and nitrocellulose membranes were incubated in NuPAGE® Transfer Buffer.
Membranes were blotted at constant voltage of 30 V for 1.5 hrs. After blotting, membranes
were washed with tris buffered saline (TBS) with TWEEN-20 (Sigma) and blocked with
Western Blocking Reagent (Roche) for 1 hour at room temperature. After blocking,
membranes were washed again and incubated with primary OATP1B1 antibody at 1:10000
dilution at 4 °C overnight. Membranes were then subsequently incubated with secondary
antibody (anti-rabbit HRP conjugate) at 1:20000 dilution at room temperature for 1 hr.
After secondary antibody incubation, membranes were washed again and soaked with
Amersham ECL Western Blotting Detection Reagents (GE) and exposed on image station
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Table 5. Protein concentrations of Lac Z and OATP1B1 variants determined by
BCA Protein Assay Kit
OATP1B1 Variant

Protein concentration (µg/µL)

Lac Z

0.97

*1a

0.95

*1b

1.09

*5

1.02

*15

0.88

G298A

0.77

C419T

0.93

C463A

0.99

C1007G

0.92

G1463C

0.99

C1738T

0.87
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to visualize. Membranes were then stripped with Restore Western Blot Stripping Buffer
(Thermo). Membranes were blocked again, incubated with actin HRP conjugate antibody
at 1:500 dilution, and visualized on image station.

3.10 RNA extraction, reverse-transcription, and quantitative
real-time PCR to analyze C1738T variant mRNA
expression
The OATP1B1 variant C1738T causes a premature stop codon that truncates the protein
before the terminal 21-mer sequence that the OATP1B1 antibody binds to, so no protein
levels were detected by immunoblot analysis. Therefore, quantitative real-time PCR was
used to quantify C1738T mRNA levels.
HeLa cells were plated in 6-well plates and transduced with OATP1B1*1a and C1738T
adenovirus. When ready, RNA was extracted using TRIzol® Reagent (Applied
Biosystems). 1 mL of TRIzol® Reagent was added to each well and incubated for 5 min at
room temperature. The contents of each well were harvested in Eppendorf tubes and 200
µL of chloroform was added to each tube and shaken for 15 sec. Tubes were incubated for
3 min at room temeperature and centrifuged at 12 000 g and 4 °C for 15 min. The clear
aqueous layer was transferred to a new tube and 500 µL of isopropanol was added. Tubes
were incubated at room temperature for 10 min and centrifuged again at 12 000 g and 4 °C
for 10 min. Supernatant was removed and the pellet was washed with 1 mL of 75% ethanol
solution. Tubes were centrifuged again at the same speed and temperature for 5 min, and
the supernatant was removed. 50 µL of RNAase-free water was used to resuspend RNA,
and RNA concentration was measured by NanoVue Plus Spectrophotometer (GE).
After RNA extraction, reverse-transcription was done using TaqMan® Reverse
Transcription Reagents (Invitrogen) to obtain cDNA. 1500 ng of OATP1B1*1a and
C1738T RNA were mixed with reverse-transcription reagents and placed in thermocycler.
cDNA was synthesized by incubating reagents for 10 min at 25 °C, followed by 30 min at
48 °C, and finally 5 min at 95 °C.
After RNA extraction and reverse-transcription to cDNA, qPCR was performed to quantify
cDNA levels of OATP1B1 *1a and C1738T. All qPCR reagents were purchased from
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Applied Biosystems®. Primers and PCR conditions are described in Table 6.
Housekeeping gene used was human 18S rRNA. OATP1B1*1a and C1738T gene
expression was detected using Fast SYBR® Green Master Mix, and 18S rRNA expression
was detected using Taqman® Fast Advanced Master Mix. ΔΔCycle threshold (Ct) was
calculated by subtracting 18S Ct from OATP1B1 Ct, and then subtracting reference gene
(*1a) ΔCt from experimental (C1738T) ΔCt. Relative gene expression is then calculated
by the formula 2^(-ΔΔCt).

3.11 Cell surface biotinylation
Cell surface biotinylation was done to isolate cell-membrane proteins. HeLa cells were
grown and transduced with Lac Z and OATP1B1 wildtype and mutant adenovirus. After
transduction, cells were washed with PBS containing 1 mM MgCl2 and 0.1 mM CaCl2
(PBS/Mg/Ca), then incubated with biotinylating agent Sulfo-NHS-SS-biotin (1.5 mg/mL,
Pierce) in PBS/Mg/Ca for 1 hour at 4 °C. Following incubation with biotin, cells were
washed with PBS/Mg/Ca containing 100 mM glycine at pH 3 and incubated for 20 min.
Cells were washed again with PBS/Mg/Ca and harvested in 700 uL of
radioimmunoprecipitation assay (RIPA) buffer (10 mM Tris-base, 150 mM NaCl, 1 mM
EDTA, 0.1% SDS, 1% Triton-X-100, protease inhibitor (Sigma), pH 7.4). Samples were
then centrifuged, and 600 uL of RIPA supernatant was mixed with 140 uL of Immunopure
Streptavidin beads (Stratagene) for 1 hour at room temperature. Samples were centrifuged
again, washed with RIPA, and the final pellet was mixed with 50 uL 2X Laemmli buffer
(0.125 M Tris-HCl pH 6.8, 10% glycerol, 2% SDS, 5% 2-mercaptoethanol, 0.01%
bromophenol blue) for 30 min at room temperature. After final centrifugation, the
supernatant was used for western blot analysis. Protein samples were separated by gel
electrophoresis, transferred to nitrocellulose membrane and probed with OATP1B1
antibody. Blots were stripped and probed with calnexin antibody (1:1000) as intracellular
control, and probed again with Na+/K+-ATPase antibody (1:500) as cell-surface control.

3.12 Rosuvastatin patient selection
Rosuvastatin cohort from a previous study by our group was obtained (52). Adult
outpatients at London Health Sciences Center (London, ON) taking daily dose of
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rosuvastatin were enrolled in the study. Patients were excluded if the last dose taken was
more than 24 hrs prior to blood draw, and all patients were on the same dose of
rosuvastatin for ≥6 weeks.

3.13 Determining OATP1B1*4 genotype
Restriction fragment length polymorphism (RFLP) was used to genotype statin patients for
OATP1B1*4. Patient DNA samples (10 ng/uL) were amplified by PCR and digested with

Table 6. Real-time PCR primers and conditions.
Primer

Sequence

Length

Tm (°C)

OATP1B1 FW

TGAACACCGTTGGAATTGC

19

65.0

OATP1B1 RV

TCTCTATGAGATGTCACTGGAT

22

58.3

PCR Conditions
Denaturation (°C)

95

Denaturation time (s)

15

Anneal/Extend (°C)

60

Extension time (s)

60

Cycles

40
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Hph-I. Primers for PCR are listed in Table 7. PCR was initialized for 5 min at 94 °C,
followed by 1 min at 94 °C, 1 min at 54 °C, and 1 min at 72 °C repeated for 35 cycles, and
concluded with 7 min at 72 °C. Total amplicon size after PCR is 532 bps. 4 units of Hph-I
was used to digest 3 µg of PCR product for 2 hrs and analyzed by gel electrophoresis.
Digested samples with 2 bands at 209 and 323 bps indicate wildtype genotype, undigested
samples with 1 band at 532 bps indicate homozygous mutant genotype, and semi-digested
products with 3 bands at 532, 209, and 323 bps indicate heterozygous genotype.

3.14 Statistical analysis
Comparison of means for transport experiments were done by Student’s t test, one-way
ANOVA, and Tukey multiple comparisons test. Multiple linear regression was done to
correlate log-transformed rosuvastatin plasma concentration with variables age, sex,
ethnicity, body mass index (BMI), dose, time since last does, and 3 OATP1B1 SNPs *1b,
*4, and *5. Additional haplotype analysis was also performed and the percentage of genetic
contribution to the observed variability was calculated by totalling the sum of squares for
each variable and calculating the proportion of the genetic component.

Table 7. RFLP PCR primers and conditions.
Primer

Sequence

Length

Tm (°C)

OATP1B1*4 FW

GATAACCCACTTAGCCTGGGG

21

64.5

OATP1B1*4 RV

ACCTGTGTTGTTAATGGGCGA

21

60.6

PCR Conditions
Denaturation (°C)

94

Annealing (°C)

54

Elongation (°C)

72

Cycles

35

35
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« Results »

4.1 MTT assay shows cells were viable at time of transport
All viral variants shows ≥80% viability compared to no virus control and were all not
significantly different from *1a variant (Fig. 3). MTT assays were performed in triplicates
on 2 separate experimental days.

4.2 Time-dependent uptake shows active transport within
the first 3 minutes
HeLa cells were transduced with Lac Z and OATP1B1*1a (wildtype) adenovirus and
incubated with substrates E1S, E217βG, and rosuvastatin for 3, 5, 10, 20, and 30 minutes.
Significant transport was observed in HeLa cells transduced with OATP1B1*1a while
minimal transport was observed in HeLa cells transduced with Lac Z. Unsaturated active
transport was observed in the first 3 minutes of uptake for all substrates, which will be the
time point used for all subsequent uptake experiments (Fig. 4).

4.3 Total uptake for 3 minutes with all substrates reveals
significant differences in uptake between OATP1B1
wildtype and variants
Single 3 minute uptake of E1S showed significantly decreased uptake in OATP1B1*1b,
*5, *15, and C419T, and almost no uptake in G298A, *9, and C1738T. Uptake in *4 and
C1007G were not significantly different from *1a, although *4 showed slightly decreased
uptake while C1007G showed slightly increased uptake (Fig. 5).
Experiments with E217βG showed similar results with significantly decreased uptake in
*1b, *5, *15, and C419T, and no uptake in G298A, *9, and C1738T. *4 again showed no
significant difference compared to *1a, but C1007G had significantly greater uptake than
*1a (Fig. 5).
Rosuvastatin single uptake experiments showed significantly decreased uptake with all
SNPs except for C1007G, which again showed slight increase in uptake but not statistically
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Figure 3. MTT assay of HeLa cells transduced with various adenovirus. Values are
expressed as percentage of no virus control. No variants were significantly different
from control (n=2).

Figure 4. Time-dependent uptake of all three substrates by wildtype OATP1B1 (*1a)
and Lac Z (n=3).
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Figure 5. Total uptake in the first 3 min of all substrates at 100 nM by HeLa cells
transduced with OATP1B1*1a and variants. Values were corrected for Lac Z and
expressed as percentage of *1a (n=3). * denotes that value is significantly different
from *1a; p<0.001.

38

significant. Only C1738T SNP seemed to completely abolish transport function as uptake
was observed in the other two SNPs that previously showed no uptake (Fig. 5).

4.4 Western blot analysis of total cellular OATP1B1
expression
Two distinct bands were observed in western blots for OATP1B1, one at ~80 kDa and one
at ~60 kDa. OATP1B1*1b, *5, and *15 SNPs all showed a decrease expression of total
OATP1B1. G298A, C419T, and *9 showed decreases in the ~80 kDa band, but more
expression of the ~60 kDa band. OATP1B1 *4 showed slight decrease in ~80 kDa band
and a slight increase in ~60 kDa band. C1007G showed increased expression of both bands
of OATP1B1. OATP1B1 was not detected in C1738T due to inability of antibody to bind
to the transporter. Actin control shows uniform protein loading (Fig. 6).

4.5 Quantitative real-time PCR analysis shows increased
production of C1738T mRNA compared to *1a
Due to C1738T variant causing a premature stop codon that prevents binding of OATP1B1
antibody to the terminal sequence, protein levels could not be detected by western blot.
qPCR was used and found that C1738T had a 1.8-fold increase in mRNA levels compared
to *1a (Fig. 7).

4.6 Concentration-dependent uptake
Uptake experiments with E1S were performed with 0.1, 0.5, 1, 2, and 5 µM of substrate
incubated for 3 minutes. No uptake was observed for variants G298A, *9, and C1738T.
Vmax was decreased for C419T and *4 and increased for C1007G, but all were not
significant from *1a. Km remained unchanged for these three SNPs (Fig 8). Intrinsic
clearance for was significantly decreased in C419T compared to *1a, slightly decreased in
*4 and remained the same in C1007G (Table 8).
Uptake experiments with E217G were performed with 0.1, 1, 5, 10, and 20 µM of substrate
incubated for 3 minutes. No uptake was observed again for variants G298A, *9, and
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C1738T. Vmax was again slightly lowered in C419T and *4, and slightly increased in
C1007G, but not statistically significant. Km in C419T and C1007G remained the same as

Figure 6. Immunlots of whole cell lysates obtained from HeLa cells transfected with
Lac Z, OATP1B1*1a and variants. Blots were probed with OATP1B1 antibody (top
panels), stripped, and probed again with actin antibody (bottom panels).
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Figure 7. mRNA expression of SLCO1B1*1a and C1738T determined by qPCR.
C1738T mRNA was 1.8-fold higher than *1a (p<0.0001).
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Figure 8. Concentration-dependent uptake of E1S by OATP1B1 wildtype and
variants. Data are expressed as mean ±S.E. (n= 3 – 5). Kinetic parameters were
obtained by non-linear curve fitting.
Table 8. Intrinsic clearance of E1S uptake by OATP1B1 wildtype and variants.
OATP1B1

Vmax/Km

*1a

17.9 ± 2.7

C419T

8.4 ± 2.2*

*4

10.9 ± 1.0

C1007G

17.3 ± 1.5

* denotes that value is significant different from *1a; p<0.05.
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*1a. *4 had an increase in Km, but still not statistically significant due to variation (Fig.
9). Intrinsic clearance was decreased in C419T, remained the same in *4, and increased in
C1007G, but all not statistically significant (Table 9).
Uptake experiments with rosuvastatin were also performed with 0.1, 1, 5, 10, and 20 µM
of substrate incubated for 3 minutes. G298A, *9, and C1738T showed no uptake again.
Vmax was unchanged in *4 and increased significantly in C1007G compared to *1a, and Km
was approximately the same for both *4 and C1007G compared to *1a. (Fig. 10). Curve
fitting could not be done for variant C419T so kinetic parameters could not be calculated.
Intrinsic clearance was about the same in *4, and increased significantly in C1007G
compared to *1a (Table 10).

4.7 Cell surface biotinylation reveals changes in cell
surface OATP1B1 expression
Cell-surface protein isolation revealed profound changes in OATP1B1 expression between
variants. G298A, and *9 variants had almost no expression of OATP1B1. C419T had a
slightly decreased expression; *4 had similar expression compared to *1a and C1007G had
an increase in expression. Calnexin, an intracellular protein, and Na+/K+-ATPase, a
membrane exclusive protein were probed to confirm cell-surface fraction (Fig. 11).

4.8 OATP1B1*4 genotyping
126 patients taking rosuvastatin were genotyped for their OATP1B1 *4 polymorphism. 85
were determined to be wildtype, 35 were heterozygous, and 6 were homozygous mutant.
Figure 12 shows restriction fragment length polymorphism analysis of undigest, wildtype,
heterozygous, and homozygous mutant samples. Patient characteristics are described in
Table 11.

4.9 Haplotype analysis of rosuvastatin patient population
Statistical analysis program R was used to predict haplotypes based on genotype. 3 SNPs:
*1b, *4, and *5 were considered in the analysis to generate a total of 7 different haplotypes
and their observed frequencies. The combination of *1b and *4 SNPs has previously been
defined as *14, and the combination of *1b and *5 has been defined as *15. However, this
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is the first time that the 3 SNPs *1b, *4, and *5 have been identified on one haplotype, and
will be defined as *37 (Table 12).

Figure 9. Concentration-dependent uptake of E217βG by OATP1B1 wildtype and
variants. Data are expressed as mean ±S.E. (n= 3 – 5). Kinetic parameters were
obtained by non-linear curve fitting.
Table 9. Intrinsic clearance of E217βG uptake by OATP1B1 wildtype and variants.
OATP1B1

Vmax/Km

*1a

6.6 ± 1.9

C419T

1.8 ± 0.4

*4

7.3 ± 0.5

C1007G

10.5 ± 1.7

44

Figure 10. Concentration-dependent uptake of rosuvastatin by OATP1B1 wildtype
and variants. Data are expressed as mean ±S.E. (n= 3 – 5). Kinetic parameters were
obtained by non-linear curve fitting.

Table 10. Intrinsic clearance of rosuvastatin uptake by OATP1B1 wildtype and
variants.
OATP1B1

Vmax/Km

*1a

0.5 ± 0.1

*4

0.7 ± 0.2

C1007G

1.5 ± 0.2*

* denotes that value is significant different from *1a; p<0.05.
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Figure 11. Immunoblot of whole cell lysates and cell-surface fractions obtained from
HeLa cells transduced with OATP1B1 wildtype and variants. Blots were probed
with OATP1B1 antibody (top panels), stripped and probed again with actin
calnexin antibody (middle panels), then stripped again and probed with Na+/K+ATPase antibody (bottom panel).

Figure 12. RFLP of wildtpe, heterozygous, and homozygous variant SLCO1B1*4
genotypes.
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Table 11. Rosuvastatin patient characteristics.
Number of patients

126

Sex (male)

88

Age (Years)

57.1 (19-80)

Ethnicity (Caucasian)

105

BMI (kg/m2)

30.4 ± 7.2

Dose (mg/kg)

0.23 ± 0.14

5 mg

19

10 mg

37

15 mg

1

20 mg

35

30 mg

2

40 mg

32

Time since last dose (hours)

13.7 ± 3.3

Minor allele frequency
SLCO1B1*1b

109/252 (43.2%)

SLCO1B1*4

47/252 (18.7%)

SLCO1B1*5

47/252 (18.7%)

Data are presented as mean (range) or mean ± SD.
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Table 12. Observed haplotypes and frequencies in rosuvastatin patient population.
*1b

*4

*5

Haplotype

Frequency

*1a

0.525

*1b

0.117

*4

0.005

*5

0.037

*14

0.166

X

*15

0.134

X

*37

0.016

X
X
X
X

X

X
X

X

X represents presence of polymorphic allele.
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4.10 Effect of haplotypes on plasma rosuvastatin
concentration
Multiple linear regression analysis of rosuvastatin patient population found that OATP1B1
*5 and *4 had significant effects on plasma rosuvastatin levels with p values of 0.0004 and
0.034 respectively, while *1b did not have significance with p value of 0.891 after adjusting
for age, sex, ethnicity, BMI, dose, and time since last dose. However, since the SNPs *4
and *5 often occurs with *1b as *14 and *15, analysis was performed correlating
haplotypes with rosuvastatin concentrations. 3 haplotypes were found to be statistically
significant after adjusting for the same variables as above. *37 positively correlated with
rosuvastatin concentration with p = 0.02096. *14 negatively correlated with rosuvastatin
levels with p = 0.00317, and *15 showed positive correlation with p = 0.00590. A full list
of haplotypes and their effect are listed in Table 13. The adjusted R2 value for this model
was 0.61. Dose and time since last dose unsurprisingly were major determinants of the
variability observed, and the genetic component of the model contributed to 14% of the
total variability with p = 0.00026 (Table 14).
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Table 13. Effect and significance of haplotypes on log-transformed plasma
rosuvastatin concentration.
Haplotype

Effect

Significance (p value)

*37

0.25

0.021

*14

-0.10

0.0032

*15

0.098

0.0059

*1b

0.0086

0.815

*4

-0.19

0.291

*5

0.10

0.151

Table 14. Contribution of variables considered in ANOVA model to variation in
plasma rosuvastatin concentration.
Variable

Sum of Squares

Haplotype

0.8903

Age

0.0094

Sex

0.0061

Ethnicity

0.0147

BMI

0.0048

Dose

4.9021

Time since last dose

0.6939
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« Discussion »

Six non-synonomous SNPs in OATP1B1 were analyzed by in vitro techniques and their
functional consequences were characterized. Loss-of-function, gain-of-function, and nulleffect SNPs were all identified. One SNP with a high MAF was genotyped in rosuvastatin
patients, and a significant correlation was found between genotype and plasma rosuvastatin
levels. These findings further demonstrate the importance of understanding OATP1B1
SNPs in statin therapy and the prediction of statin-induced myopathy.

5.1 In vitro data show consistent results among substrates
In vitro functional analyses were performed with 3 different substrates E1S, E217G, and
rosuvastatin, and the effect of each SNP was consistent for each substrate. Substratedependent differences have often been shown by previous studies involving OATP1B1
SNPs and these substrates, but were not seen here (31). Transport for all substrates were
totally abolished in G298A, *9, and C1738T variants, decreased in C419T, increased in
C1007G, and unaffected in *4 (Table 15). The absence of substrate-dependent differences
suggest that these SNPs are not located at sites of substrate recognition, and that the
changes induced by these SNPs are purely due to changes in protein structure or interaction
between the transporter and other proteins that changes the expression of the transporter.

5.2 No significant differences in intrinsic clearance was
observed in OATP1B1 variants that exhibited transport
Concentration-dependent uptake studies were performed with all 6 OATP1B1 variants, and
the results were analyzed by non-linear curve fitting to calculate Vmax and Km.
Subsequently, intrinsic clearances (Vmax/Km) were calculated and compared against
wildtype. G298A, *9, and C1738T variants did not exhibit any transport activity with any
substrate, so Michaelis-Menten kinetic parameters could not be calculated. This is
consistent with total uptake results as these variants also showed minimal total uptake.
For E1S, Vmax and Km were calculated for wildtype and variants C419T, *4, and C1007G.
No significant differences were observed for Vmax and Km of any of these variants compared
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Table 15. Summary of in vitro findings for all substrates and OATP1B1 variants.
G298A

C419T

*4

C1007G

*9

C1738T

E1S

No
transport

Reduced
transport

No
Change

Increased
transport

No
transport

No
transport

E217βG

No
transport

Reduced
transport

No
Change

Increased
transport

No
transport

No
transport

Rosuvastatin

No
transport

Reduced
transport

No
Change

Increased
transport

No
transport

No
transport
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to wildtype (Fig. 8). Looking at intrinsic clearance, only C419T had a significantly lower
intrinsic clearance, which is consistent again with total uptake data (Table 8). *4 had
slightly lower intrinsic clearance that was not statistically significant while C1007G had
similar intrinsic clearance compared to wildtype. Both of these observations were also
consistent with total uptake of E1S (Fig. 5).
For E217G uptake, Vmax and Km were again calculated for wildtype and variants C419T,
*4, and C1007G. Vmax, Km, and intrinsic clearance for the variants were all not significantly
different compared to wildtype, but show a similar trend as uptake with E1S. C419T had
slightly lower intrinsic clearance, *4 had intrinsic clearance similar to wildtype, and
C1007G had slightly higher intrinsic clearance (Fig. 9, Table 9). This again is consistent
with total uptake results with E217G which showed significantly lower uptake by C419T,
no change in uptake with *4, and significantly higher uptake with C1007G (Fig. 5).
For rosuvastatin uptake, Vmax and Km could only be calculated for wildtype and variants
*4 and C1007G. Uptake was observed for C419T, but curve fitting did not reach an
asymptote and therefore kinetic parameters could not be determined (Fig. 10). Increasing
drug concentration beyond 20 µM in an attempt to extend the curve proved to be toxic to
cells and could not be done. There were again no significant differences in Vmax and Km of
variants compared to wildtype (Fig. 10). Intrinsic clearance of *4 was again similar to
wildtype, and intrinsic clearance of C1007G was significantly greater than wildtype (Table
10). Although intrinsic clearance of C419T could not be calculated, it can be seen on the
graph that it seems to have lower Vmax compared to wildtype (Fig. 19). These results are
again in agreement with total uptake results as well as the intrinsic clearances of these
variants with the other two substrates (Fig. 5).
Although the intrinsic clearances were not statistically significant for most of the variants,
it is apparent that for the variants exhibiting transport, the transport activity from lowest to
highest is ordered: C419T, *4, and C1007G, with wildtype transport activity around the
same as *4.

53

5.3 Changes in total transport is mediated by changes in
transporter expression and not intrinsic transporter
kinetics
Immunoblots for whole cell lysates of HeLa cells overexpressing OATP1B1 show 2 bands
of OATP1B1 at ~80 kDa and ~ 60 kDa (Fig 6). The ~80 kDa OATP1B1 is a glycosylated
version of the protein, and has been proposed to be the stable version expressed at the cell
membrane. The ~60 kDa protein is unglycosylated, and as a result is unstable and likely
degraded before implanted in the membrane (30, 80). Therefore it would be reasonable to
assume that the expression of ~80 kDa protein would correlate with transport activity,
which is observed here. Variants G298A, C419T, and *9 all have strong expression of the
~60 kDa band and very week or no expression of the ~80 kDa band, and these variants
were determined to have weak or no transport activity. *4 variant has slightly weaker
expression of ~80 kDa band, and therefore has no changes in total transport with E1S and
E217G and slightly lower transporter with rosuvastatin. C1007G variant has much stronger
expression of ~80 kDa band, and is again correlated with higher total transport of all
substrates.
Concentration-dependent uptake studies revealed few significant differences in intrinsic
clearance with most variants. Intrinsic clearance was significantly lower for C419T when
transporting E1S, and significantly higher for C1007G when transporting rosuvastatin.
Overall, the lack of significance show that intrinsic properties of the transporter were not
altered. Therefore the SNPs investigated in this study do not significantly change
transporter structure, but rather protein-protein interaction and transporter expression.

5.4 Cell membrane fraction exclusive expresses ~80 kDa
OATP1B1 and correlates strongly with transport activity
Cell-surface biotinylation was used to isolate membrane bound proteins, and the isolated
fraction was probed with OATP1B1 antibody. Unlike whole cell lysates where 2 bands
were identified at ~80 kDa and ~60 kDa, only 1 band at ~80 kDa was observed (Fig. 11).
This is consistent with the idea that ~80 kDa OATP1B1 is stably expressed at the cell
membrane and the ~60 kDa version is not (80). Furthermore, the strength of the ~80 kDa
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band correlates very well with total uptake, similar to but more profound than the
correlation seen with whole cell lysates. *4 variant has cell membrane OATP1B1
expression comparable to that of wildtype, and therefore also have similar transport
activity. C419T has decreased expression and decreased transport compared to wildtype.
C1007G has increased expression with higher transport compared to wildtype. G298A, *9,
and C1738T variants have minimal or no expression of OATP1B1, and predictably have
no transport activity. This data shows again that transport activity is more strongly dictated
by cell surface expression level of ~80 kDa OATP1B1, and less so by intrinsic activity of
the transporter.

5.5 OATP1B1*4 SNP is more prominent in Caucasian
population
NCBI database reports the OATP1B1 *4 variant to have a MAF of 0.0785. Detailed look
at NCBI data revealed Americans with European descent to have the highest frequency of
heterozygotes compared to all other ethnicities. In our rosuvastatin patient population, 126
patients were genotyped for *4 SNP and a MAF of 0.18 was observed, more than double
the MAF reported by NCBI. Out of 126 patients, 105 identified to be Caucasian and 21
were non-Caucasian (Table 11). MAF within the Caucasian population was slightly higher
at 0.20 and out of the 21 non-Caucasians, only 3 were observed to be heterozygous and the
rest were homozygous wildtype. This shows that the variant allele of OATP1B1 *4 may
have higher frequency in Caucasians than other ethnicities.

5.6 OATP1B1 genotype significant contributes to variability
in plasma rosuvastatin concentrations
Variables age, sex, ethnicity, BMI, dose, time since last dose, and 7 different observed
haplotypes were analyzed in a regression model against log-transformed rosuvastatin
plasma concentrations. It was determined that the genotype, dose, and time since last dose
were significant contributors to variability in plasma rosuvastatin concentrations, with the
genotype contributing 14% (Table 14). If dose and time since last dose are excluded from
the model, genotype contributes to 97% of the observed variability, which means that apart
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from dosage, almost all the variability in plasma rosuvastatin concentrations stem from the
SNPs *1b, *4, and *5.

5.7 OATP1B1*4 almost always occurs with *1b as *14 and
correlates with lower plasma rosuvastatin
concentrations
OATP1B1 *4 and *14 were characterized in 2001 but have not been studied in detail since.
After genotyping rosuvastatin patients for OATP1B1 *4, it was observed that carriers for
*4 were almost always also carriers for *1b. Using haplotype analysis, it was revealed that
the *4 genotype alone only has a frequency of 0.5% while the *14 genotype has a frequency
of 17% (Table 12).
OATP1B1 *14 is significantly correlated with lower plasma rosuvastatin levels with p =
0.003. Patients with the *14 haplotype would be predicted to have lower chance of
rosuvastatin-induced myopathy due to lower plasma levels (Table 13). A recent study
found that *14 correlated with lower atorvastatin AUC (91). This is consistent with our
findings and further show that *14 may be a protective genotype for statin therapy.
Previous findings of OATP1B1 *1b have been controversial in correlating genotype with
drug concentrations (31). This could be due to lack of consideration of *4. Since *14 is
fairly common in the population, it is likely that many individuals genotyped as *1b is
actually *14. While *14 significantly affects rosuvastatin concentrations and *1b does not,
it would explain to a degree the variability seen in studies examining the *1b genotype.

5.8 In vitro data with *4 does not correlate with in vivo
findings
Total uptake and kinetic data with *4 polymorphism showed that it has a very moderately
decreased to no change in uptake compared to wildtype. Interestingly, total uptake with
rosuvastatin actually showed a significantly decreased uptake (Fig. 5). This would mean
that patients that are carriers for *4 should have significantly higher rosuvastatin
concentrations due to impaired hepatic uptake. However, this is not the case as seen above.
Although in vitro studies with *14 were not conducted, previous studies showed that *14
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does not show significantly different uptake compared to *1a (76). Since functional studies
showed that changes in cell-surface expression was the primary driver of changes in
transport, it is likely that there are regulatory mechanisms affected by *14 that increased
the expression of OATP1B1 at the basolateral membrane of hepatocytes. There is a great
amount of variation in OATP1B1 expression in the liver that cannot be explained by
genetics, and the mechanisms of this variation remain unknown (93). With further research
into the regulatory mechanisms of OATP1B1 expression, we may be able to identify the
reason that *14 is correlated with lower plasma rosuvastatin levels.

5.9 Carriers for C1007G may have decreased chance of
statin-induced myopathy
Although data with *4 did not suggest correlation between in vitro and in vivo results,
previous studies with *5 and *15 did show strong correlation with decreased uptake in vitro
and increased statin concentrations in vivo (76, 80). Therefore it is possible that carriers for
the gain-of-function polymorphism C1007G would have a more active OATP1B1, and thus
have better hepatic uptake of statins and lower risk for myopathy. Since this polymorphism
is rare, it was not genotyped in our population. It would be interesting to see in a larger
population if this SNP significantly affects plasma statin levels.

5.10 Conclusions
The results partly support the hypothesis that OATP1B1 variants will have decreased
transport of the substrates E1S, E217βG, and rosuvastatin compared to wildtype. Variants
G298A, C419T, *9, and C1738T all exhibited decreased uptake, while *4 showed no
significant difference in uptake and C1007G showed an increase in uptake. The *4
findings are consistent with previous in vitro data, but it was surprising to find C1007G to
be a gain-of-function polymorphism. The mechanism for the gain-of-function is unknown
and would require deeper insight into the tertiary structure of the transporter. The changes
in uptake observed were all facilitated by changes in cell-surface expression, and not by
changes in Vmax or Km.
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Only SLCO1B1*4 was studied in vivo due to its high MAF. Contrary to the hypothesis,
carriers for this allele had lower plasma rosuvastatin concentrations despite it having no
effect on the uptake of rosuvastatin in vitro. This shows that a SNP’s in vitro effect can
be opposite of its in vivo effect, and that polymorphisms in the transporter can affect
other biological mechanisms apart from intrinsic transporter properties to generate an
overall in vivo effect.
This study was successful in determining new pharmacogenomic predictors for plasma
statin levels. Patients carrying the SLCO1B1*14 genotype are predicted to have lower
plasma rosuvastatin concentrations and have lower chance of experiencing statin-induced
myopathy, so their rosuvastatin dosing can be more aggressive to achieve desired LDL-C
levels.

5.11 Limitations
One of the significant limitations of the adenoviral expression system is that there is no
control of the amount of transporter expressed other than transducing cells with the same
MOI of adenovirus. The viral production machinery in cells may vary and each cell would
be expressing a different amount of transporter. Also, a different adenovirus is generated
for each SNP, so it is assumed that the different viruses have the same capacity for
infection. This however may not be the case and may be the cause for difference in
OATP1B1 expression rather than the SNPs.
Protein expression for C1738T could not be analyzed by western blot due to the absence
of C-terminus sequence that the antibody binds to. Although mRNA levels were measured,
it is not a perfect predictor of what occurs at the protein level. It is likely that the protein is
degraded prematurely and is not implanted at the membrane, but an antibody that binds to
another sequence along the protein would confirm expression of the protein. However
OATP1B1 antibodies are not common and the one used in this study is the only one
available and functional.
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5.12 Future directions
OATP1B1 SNPs and pharmacogenomics in general have advanced a long way since the
Human Genome Project. There is now undeniable evidence that personalized medicine can
improve clinical outcomes (33). Pharmacogenomics began with the identification of SNPs
and other small genetic variations, but it is now economically feasible to sequence entire
genes to search for novel SNPs and other types of genetic differences that can contribute
to variation in drug response. Patients experience severe cases of statin-induced myopathy
can have hundreds of candidate genes sequenced that may contribute to statin
pharmacokinetics, and genetic differences can be noted and compared with other
individuals. By sequencing entire genes, rare or novel mutations would be identified. Since
the approach starts with a phenotype and works backwards to identify a genotype, the
genetic variations observed are more likely to have clinical significance. The genetic
differences found by this method can then be taken back to the lab and functionally
analyzed in in vitro or in vivo models with the knowledge of the corresponding clinical
phenotype. With sequencing of entire genes, there would surely be a rapid growth in the
number of clinically significant mutations, and would greatly enhance the impact of
personalized medicine.
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